VIDEO: How a port delivery system can reduce treatment burden

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify cperla@healio.com if there are concerns regarding accuracy of the transcription.

Port delivery system and the way it delivers a continuous dose of ranibizumab is a huge advancement in maintaining and improving visual acuity in patients with neovascular AMD. In the study, there are very few patients had failed the drug at a six month period of time. And, as a result, even a large number of patients, even went a year to a year-and-a-half out before they required refill therapy with this device. I think that the device is very elegant in design and obviously had a lot of advantages over intravitreal therapy. It may allow for less frequent evaluation and management, maybe every quarter, every six months, per se, but truly has a huge benefit to our patients. The one major risk factor we're concerned with SUSVIMO is the rate of infection, which was significantly higher than that we do in intravitreal injections. And so, therefore, SUSVIMO was actually given a black box warning about its rate of intraocular inflammation and infection, potentially with the implant over time.